Demand5 Apr 2021 09:27
Looks like Big Al was deramping in the last presentation
-Effective disease control (R < 1) probably requires 30M people in the UK are tested/test themselves once per week: the potential UK only • • Therefore the commercial opportunity for demand. Avacta market size is ~120M tests per month. is determined by supply capacity not Supply capacity is dependent upon multiple factors including: • • • • • Raw materials supply (nitrocellulose strip ( reagents. LFD strip manufacture and assembly. Cytiva ), Affimer Plasticware (saliva collection tube, transfer pipette). Test kit assembly and logistics. reagents ( OEM deals have the potential to expand the commercial opportunity for Avacta)
https://avacta.com/wp-content/uploads/2020/09/Avacta-Group-plc-Interim-Results-September-2020-v2.pdf
Also from the last business update
Avacta will immediately be able access initial manufacturing capacity through Mologic, in addition to scale-up manufacturing capacity with BBI and Abingdon Health. Combined, these manufacturing partnerships can scale up to several million tests per month and potentially much higher with further investment. Avacta is also continuing its discussions with other manufacturers in the UK and overseas in order to be able to access additional capacity to ensure that it can meet the expected demand.
The Group continues its commercial discussions with potential customers for the AffiDX® SARS-CoV-2 Lateral Flow Rapid Antigen Test and expects demand to be present for rapid testing for at least two years and probably for longer. Only by having a high-quality test that identifies the majority of infectious individuals can this clinical need be translated into commercial success and the Group believes that the recent initial clinical data are extremely encouraging in that regard.
We can't meet the capacity they are looking at with UK manufacturing alone, those extra discussions with manufacturers in the UK and overseas will be crucial.
MASSIVE week coming, no more false dawns